Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Larotrectinib ====== Larotrectinib, a selective inhibitor of tropomyosin receptor kinase, has been effective in pediatric tumors with [[Neurotrophic Tyrosine Receptor Kinase]] (NTRK) fusion mutations in children as young as 1-month-old. Offenbacher et al. shared the case of a 9-month-old boy who presented with a 4-month history of regression of his milestones and severe [[constipation]] who was found to have a large [[spinal pilocytic astrocytoma]] with multiple intracranial periventricular lesions ((Offenbacher R, Kobets A, Dalvi N, Hsu K, Chin S, Snuderl M, Levy A, Martin A. A nine-month-old boy with regression of milestones and severe constipation: an unusual case of a large spinal NTRK1 fusion pilocytic astrocytoma. Childs Nerv Syst. 2022 Sep 15. doi: 10.1007/s00381-022-05662-w. Epub ahead of print. PMID: 36107222.)) larotrectinib.txt Last modified: 2024/06/07 02:58by 127.0.0.1